<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8454">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996890</url>
  </required_header>
  <id_info>
    <org_study_id>MV-ZIKA-101</org_study_id>
    <secondary_id>2016-004212-34</secondary_id>
    <nct_id>NCT02996890</nct_id>
  </id_info>
  <brief_title>Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability</brief_title>
  <official_title>Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Themis Bioscience GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Themis Bioscience GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in
      48 healthy volunteer subjects.

      After completion of screening procedures, the subjects are randomized to one of four
      treatment groups (different dosage strengths and placebo) All subjects will receive study
      treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with
      two vaccinations will receive a second treatment at day 28.

      Subjects will return on day 56 for the final visit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: Functional anti-Zika antibodies as measured by PRNT</measure>
    <time_frame>56 days</time_frame>
    <description>Functional anti-Zika antibodies as measured by PRNT.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Zika Virus</condition>
  <arm_group>
    <arm_group_label>High dose - single shot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV-ZIKA, high dose, one vaccination, day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV-ZIKA, low dose, two vaccinations, day 0 and day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV-ZIKA, high dose, two vaccinations, day 0 and day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline, two treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MV-ZIKA</intervention_name>
    <description>MV-Zika vaccine</description>
    <arm_group_label>High dose - single shot</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>physiological saline</description>
    <arm_group_label>High dose - single shot</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers aged 18 to 55

          -  subjects of child bearing potential must perform reliable method of contraception

        Exclusion Criteria:

          -  immune deficiency, history of HIV, HBV, HCV

          -  drug addiction

          -  vaccination within 4 weeks prior to study or planned vaccination during study

          -  prior receipt of any Zika vaccine

          -  recent infection 1 week prior to screening

          -  relevant medical history interfering with aim of study

          -  neoplastic disease, hematological malignancy

          -  history of autoimmune disease

          -  psychological condition that affects ability to participate in the study

          -  history of severe adverse reactions to vaccine administration

          -  history of anaphylaxis

          -  allergic reactions, abnormal lab values, or concomitant medication per decision of
             the investigator

          -  use of immunosuppressive drugs within 30 days before screening or planned use during
             study

          -  receipt of blood products within 120 days before screening or planned use during
             study

          -  pregnancy, unreliable contraception method

          -  decision of the investigator

          -  regular blood plasma donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raimund M. Vielnascher, MSc</last_name>
    <phone>+43 676 843496</phone>
    <phone_ext>421</phone_ext>
    <email>raimund.vielnascher@themisbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Pfeiffer, MSc</last_name>
    <phone>+43 676 843496</phone>
    <phone_ext>420</phone_ext>
    <email>andrea.pfeiffer@themisbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Wiedermann, MD, PhD</last_name>
      <phone>+43 1 40160</phone>
      <phone_ext>33101</phone_ext>
      <email>ursula.wiedermann-schmidt@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christa Firbas, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29970</phone_ext>
      <email>christ.firbas@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Schranz</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29970</phone_ext>
      <email>sabine.schranz@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Schwameis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Sch√∂rgenhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva-Luise Hobl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>December 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
